Phreesia, Inc. PHR

Phreesia, Inc. es un proveedor de soluciones de software. La empresa ofrece una plataforma tecnológica basada en software como servicio (SaaS), llamada Plataforma Phreesia, que ofrece a los clientes de servicios de salud una suite de soluciones integradas que gestionan el acceso de pacientes, registro, pagos y soporte clínico. Su plataforma opera como una plataforma única, unificada y multiinquilino que ha demostrado escalabilidad e integración perfecta dentro de la infraestructura operativa de sus clientes de servicios de salud. La plataforma de la empresa ofrece diversas soluciones a sus clientes, que incluyen citas, registro, ciclo de ingresos, soporte clínico, ofertas de productos COVID-19, activación de pacientes y soluciones de ciencias de la vida. Sirve a una variedad de clientes proveedores que van desde consultas de especialidades únicas, que incluyen medicina interna y familiar, urología, dermatología y ortopedia, hasta grupos de especialidades múltiples y sistemas de salud, así como pagadores regionales y nacionales y otras organizaciones.

• The Motley Fool 8 sept

  Why Phreesia Stock Got Knocked Down Today

  Phreesia stock fell 6.58% after Raymond James analyst John Ransom downgraded the company from outperform to market perform. The downgrade was triggered by concerns over declining organic revenue growth that could turn negative in H2, combined with worries about AI spending pressuring EBITDA and potential budget constraints among healthcare provider customers. Despite 10% YoY revenue growth and nearly tripled profitability in Q2, the company missed earnings expectations.

  

• The Motley Fool 3 sept

  Why Phreesia Stock Tumbled Today

  Phreesia (PHR) stock fell 6.33% after reporting Q2 fiscal 2027 earnings that missed analyst expectations on net income despite beating revenue estimates. While the company posted strong net income growth to $1.9 million ($0.03 per share) and 10% revenue growth to $129.5 million, analysts expected $0.09 per share in earnings. The company maintained full-year guidance and highlighted new products AccessOne and ProviderConnect, but the analyst recommends holding off on investment given the modest performance and ongoing restructuring.

  

• Zacks Investment Research 2 sept

  Phreesia (PHR) Q2 Earnings and Revenues Lag Estimates

  Phreesia reported Q3 2026 earnings of $0.03 per share, missing consensus estimates of $0.11 by 72.73%, though revenues slightly missed expectations at $129.46M. The stock has underperformed the S&P 500 by 41.5% year-to-date. With a Zacks Rank #3 (Hold) rating and mixed estimate revisions, the stock is expected to perform in line with the market near-term.

  

• GlobeNewswire Inc. 12 jul

  Bronstein, Gewirtz & Grossman LLC Urges Phreesia, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

  A class action lawsuit has been filed against Phreesia, Inc. alleging securities fraud. The complaint claims the company made false statements about its business prospects while experiencing slowing demand, diminished revenue visibility, and weakened pharmaceutical marketing commitments in its Network Solutions segment during the period from May 8, 2025 to March 30, 2026.

  

• GlobeNewswire Inc. 10 jul

  רוזן, עורך דין מוביל בתחום המשפט, מעודד את משקיעי מיקרוסופט לקבל ייעוץ משפטי לפני המועד האחרון החשוב בתביעה ייצוגית לניירות ערך – MSFT

  Rosen Law Firm, an investor rights law firm, is notifying shareholders of Microsoft Corporation and other companies about important deadlines for joining securities class action lawsuits. The firm alleges that Microsoft made false statements regarding its Copilot product line's performance issues, competitive positioning, and failure to convert users to paid subscriptions, resulting in investor losses.